CA2342773A1 - Interferon-epsilon - Google Patents

Interferon-epsilon Download PDF

Info

Publication number
CA2342773A1
CA2342773A1 CA002342773A CA2342773A CA2342773A1 CA 2342773 A1 CA2342773 A1 CA 2342773A1 CA 002342773 A CA002342773 A CA 002342773A CA 2342773 A CA2342773 A CA 2342773A CA 2342773 A1 CA2342773 A1 CA 2342773A1
Authority
CA
Canada
Prior art keywords
interferon
amino acid
seq
acid residues
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002342773A
Other languages
English (en)
Inventor
Darrell C. Conklin
Francis J. Grant
Mark Rixon
Wayne Kindsvogel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2342773A1 publication Critical patent/CA2342773A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)

Abstract

Les interférons représentent une classe importante de produits biopharmaceutiques aux propriétés biologiques efficaces pour traiter divers troubles médicaux, et notamment certaines maladies auto-immunes et certains cancers, ces interférons améliorant par ailleurs la réponse immunitaire contre les agents infectieux. Alors qu'à ce jour, quatre types d'interférons ont été identifiés chez les humains : l'interféron-.alpha., l'interféron-.beta., l'interféron-.gamma., et l'interféron-.omega.. La présente invention concerne de nouvelles formes d'un interféron humain et murin, l'"interféron-.epsilon.", qui peut être utilisé dans les domaines diagnostique et thérapeutique.
CA002342773A 1998-09-18 1999-09-16 Interferon-epsilon Abandoned CA2342773A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US15706898A 1998-09-18 1998-09-18
US09/157,068 1998-09-18
US24529399A 1999-02-05 1999-02-05
US09/245,293 1999-02-05
US35023299A 1999-07-08 1999-07-08
US09/350,232 1999-07-08
PCT/US1999/021279 WO2000017361A2 (fr) 1998-09-18 1999-09-16 Interferon-epsilon

Publications (1)

Publication Number Publication Date
CA2342773A1 true CA2342773A1 (fr) 2000-03-30

Family

ID=27387961

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002342773A Abandoned CA2342773A1 (fr) 1998-09-18 1999-09-16 Interferon-epsilon

Country Status (6)

Country Link
EP (1) EP1141296A2 (fr)
JP (1) JP2002526078A (fr)
AU (1) AU6042599A (fr)
CA (1) CA2342773A1 (fr)
IL (1) IL142061A0 (fr)
WO (1) WO2000017361A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020025304A1 (en) * 2000-06-16 2002-02-28 Croze Edward M. Novel interferon for the treatment of multiple sclerosis
WO2005074524A2 (fr) 2004-02-02 2005-08-18 Ambrx, Inc. Polypeptides de l'interferon humain modifies et leurs applications
CA2590462C (fr) 2004-12-22 2017-02-28 Ambrx, Inc. Procedes pour l'expression et la purification d'hormone de croissance humaine recombinante
BRPI0519170A8 (pt) 2004-12-22 2018-05-08 Ambrx Inc formulações de hormônio de crescimento humano que compreendem um aminoácido não naturalmente codificado
EP2284191A3 (fr) 2004-12-22 2011-07-20 Ambrx, Inc. Procédé de préparation de hGH
WO2011153590A1 (fr) * 2010-06-09 2011-12-15 Monash University Utilisation de l'interferon epsilon dans des procédés de diagnostic et de traitement
EP3574003A4 (fr) 2017-01-30 2020-12-02 Hudson Institute of Medical Research Méthode de traitement
CN111420033A (zh) * 2020-03-30 2020-07-17 温州肯恩大学(Wenzhou-KeanUniversity) 人干扰素 -ε在肿瘤治疗中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4614651A (en) * 1981-07-12 1986-09-30 Damon Biotech, Inc. Interferon epsilon
NO832517L (no) * 1982-07-12 1984-01-13 Damon Biotech Inc Interferonpreparat, samt fremgangsmaate for dets fremstilling
CA2311681A1 (fr) * 1997-12-08 1999-06-17 Genentech, Inc. Interferon-epsilon humain: interferon de type 1

Also Published As

Publication number Publication date
WO2000017361A2 (fr) 2000-03-30
EP1141296A2 (fr) 2001-10-10
JP2002526078A (ja) 2002-08-20
AU6042599A (en) 2000-04-10
WO2000017361A3 (fr) 2001-07-26
IL142061A0 (en) 2002-03-10

Similar Documents

Publication Publication Date Title
EP1860188B1 (fr) Récepteur de cytokine humain
US6548056B2 (en) Murine interferon-α
CA2342773A1 (fr) Interferon-epsilon
US6329175B1 (en) Interferon-ε
AU4825000A (en) Autotaxin variants and uses to treat diseases of metabolism
WO2000055324A1 (fr) Interferon alpha murin egalement appele zcyto13
US20030017980A1 (en) Mammalian Wnt polypeptide-5
US20030175897A1 (en) Human interferon, Zinf2
AU2002324476A8 (en) Human cytokine receptor
WO2002004519A2 (fr) Recepteur de cytokine murin
CA2358873A1 (fr) Polypeptide humain avec multiples domaines du type facteur de croissance epidermique (egf), denomme zntr2
MXPA01002817A (es) Interferon - epsilon
WO2000018796A2 (fr) Proteine secretoire 48
US20020132996A1 (en) Secretory protein-48
CA2360577A1 (fr) Zlrr3: proteine humaine repetee riche en leucine
US20020151013A1 (en) Zalpha13: a human secreted protein
US20020142396A1 (en) Mammalian cystatin-8 and its use to inhibit cancer procoagulant protein
CA2393527A1 (fr) Trousse pedagogique et methode utilisant un gene et une proteine stimule par le facteur de necrose tumorale
EP1326979A2 (fr) Proteine de liaison au nucleotide cyclique humain
WO2000063378A2 (fr) Zalpha13: proteine humaine secretee

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20090521